Business
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 20
About this update from Entrada Therapeutics, Inc.
[{"type":"image","alt":"Entrada Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Entrada Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":67,"url":"https://media.zenfs.com/en/globenewswire.com/35b6e002db33bd5d921cdc15c7548cc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4ZOjTfuHNlSZ7em_8u_z.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/35b6e002db33bd5d921cdc15c7548cc1","width":300,"height":67}},"lazy":false},{"type":"text","content":"-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –","length":142,"tagName":"p"},{"type":"text","content":"-- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 –","length":163,"tagName":"p"},{"type":"text","content":"-- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 –","length":197,"tagName":"p"},{"type":"text","content":"-- Cash runway into Q3 2027 –","length":29,"tagName":"p"},{"type":"text","content":"-- Entrada to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET) --","length":141,"tagName":"p"},{"type":"text","content":"BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported progress across its robust development portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.","length":235,"tagName":"p"},{"type":"text","content":"“In 2025, we strategically positioned Entrada to significantly advance what we believe to be best-in-class therapies for people living with Duchenne muscular dystrophy, and expanded our pipeline into ocular diseases with the selection of our first clinical candidate targeting Usher syndrome, an inherited retinal disorder with a profound unmet clinical need,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “2026 will be a data-rich year for our Duchenne franchise, with multiple readouts including data from the first cohort of ELEVATE-44-201 expected in the secon...